FDA clears Quotient's transfusion diagnostic monoclonal antibodies
This article was originally published in Clinica
The US FDA has approved a biologics licence application (BLA) for 15 monoclonal antibodies from Quotient Biodiagnostics, for use in transfusion diagnostics. The Newtown, Pennsylvania firm is developing a proprietary line of products, ALBAclone, to type and screen blood in blood donor centres, reference labs and hospitals. The BLA includes products for forward blood typing, where a patient's blood sample is mixed with serum – such as Anti-A, Anti-B and Anti-D, and some rare anti-sera including Anti-K and Anti-M. Quotient is planning further submissions to the FDA to complete its portfolio of manual reagents, including red cells for reverse typing – where a patient's serum is mixed with a known blood type – antibody screening and identification, and anti-human globulin.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.